The Wall Street Journal |
Health Blog
By Katherine Hobson
A lot of eyes in the pharma
world are focused on how the introduction of a generic version of Lipitor
will affect the market for the cholesterol-fighting drug.
Last week, for example,
researchers published
an analysis in the New England Journal of
Medicine that found cost savings from switches to the generic version of
atorvastatin could reach $4.5 billion annually by 2014, with the generic
grabbing 44% of the entire statin market three years after going on sale.